Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Hüttmann, A.
1292  Ergebnisse:
Personensuche X
?
1

BRECADD IS NON‐INFERIOR TO EBEACOPP IN PATIENTS WITH ADVANC..:

Borchmann, P. ; Moccia, A. A. ; Greil, R....
Hematological Oncology.  41 (2023)  S2 - p. 881-882 , 2023
Link: https://doi.org/10.1002/..
 
?
2

A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PR..:

Davies, A. J. ; Zucca, E. ; Ceriani, L....
Hematological Oncology.  41 (2023)  S2 - p. 48-50 , 2023
Link: https://doi.org/10.1002/..
 
?
3

Ibrutinib + bortezomib + R‐CHOP for higher‐risk DLBCL: Feas..:

Denker, S. ; Bittner, A. ; Frick, M....
Hematological Oncology.  41 (2023)  S2 - p. 424-425 , 2023
Link: https://doi.org/10.1002/..
 
?
4

ROMIDEPSIN PLUS CHOP VERSUS CHOP IN PATIENTS WITH PREVIOUSL..:

Camus, V. ; Thieblemont, C. ; Gaulard, P....
Hematological Oncology.  41 (2023)  S2 - p. 77-78 , 2023
Link: https://doi.org/10.1002/..
 
?
5

Toxicities at one year follow‐up in patients with advanced ..:

Ferdinandus, J. ; Moccia, A. A. ; Greil, R....
Hematological Oncology.  41 (2023)  S2 - p. 363-364 , 2023
Link: https://doi.org/10.1002/..
 
?
6

The ECHELON-2 Trial: 5-year results of a randomized, phase ..:

Horwitz, S. ; O'Connor, O.A. ; Pro, B....
Annals of Oncology.  33 (2022)  3 - p. 288-298 , 2022
Link: https://doi.org/10.1016/..
 
?
7

Cost-Effectiveness of Shortening Treatment Duration Based o..:

Greuter, MJE ; Eertink, JJ ; Jongeneel, G...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  6 - p. 382-392 , 2022
Link: https://doi.org/10.1016/..
 
?
8

PHASED VARIANTS IMPROVE DLBCL MINIMAL RESIDUAL DISEASE DETE..:

Kurtz, D. M ; Chabon, J. J ; Soo, J...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
9

CLONAL HEMATOPOIESIS IS ASSOCIATED WITH INFERIOR PROGNOSIS ..:

Boegeholz, J ; Alig, S ; Sworder, B...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
10

IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PR..:

Martelli, M. ; Zucca, E. ; Botto, B....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
11

Optimal timing and criteria of interim PET in DLBCL: a comp..:

Eertink, J. J. ; Burggraaff, C. N. ; Heymans, M. W....
Blood Advances.  5 (2021)  9 - p. 2375-2384 , 2021
Link: https://doi.org/10.1182/..
 
?
12

RESPONSE TO A+CHP BY CD30 EXPRESSION IN THE ECHELON‐2 TRIAL:

Illidge, T. ; Horwitz, S. ; Iyer, S....
Hematological Oncology.  37 (2019)  S2 - p. 281-283 , 2019
Link: https://doi.org/10.1002/..
 
?
13

Single top production at HERA in the Standard Model and its..:

Hollik, W. ; Hüttmann, A. ; Kniehl, B.A.
Nuclear Physics B.  790 (2008)  1-2 - p. 200-215 , 2008
Link: https://doi.org/10.1016/..
 
?
14

Clonal Cultures in vitro for Haemopoietic Cells Using Semis..:

, In: Cell Biology,
LI, C ; HUTTMANN, A ; LAU, E - p. 115-120 , 2006
Link: https://doi.org/10.1016/..
 
?
15

Granulocyte colony–stimulating factor–induced blood stem ce..:

Hüttmann, A. ; Dührsen, U. ; Stypmann, J....
Basic Research in Cardiology.  101 (2005)  1 - p. 78-86 , 2005
Link: https://doi.org/10.1007/..
 
1-15